STUDYID	DOMAIN	TSPARMCD	TSPARM	TSVAL	TESCDREF
DIAA-2025-001	TE	ADDON	Added on to Existing Treatments	N	CDISC
DIAA-2025-001	TE	AGEMAX	Planned Maximum Age of Subjects	80	ISO 8601
DIAA-2025-001	TE	AGEMIN	Planned Minimum Age of Subjects	18	ISO 8601
DIAA-2025-001	TE	LENGTH	Trial Length	P7M	ISO 8601
DIAA-2025-001	TE	PLANSUB	Planned Number of Subjects	100	
DIAA-2025-001	TE	SEXPOP	Sex of Participants	BOTH	CDISC CT
DIAA-2025-001	TE	STOPRULE	Study Stop Rules	Trial stops if serious adverse events > 80%	CDISC CT
DIAA-2025-001	TE	TBLIND	Trial Blinding Schema	DOUBLE-BLIND	CDISC CT
DIAA-2025-001	TE	TCNTRL	Control Type	PLACEBO	CDISC CT
DIAA-2025-001	TE	TITLE	Trial Title	DIABETES TREATMENT EFFICIENT EVALUATION TRIAL	
DIAA-2025-001	TE	TPHASE	Trial Phase Classification	Phase II Trial	CDISC CT
DIAA-2025-001	TE	TTYPE	Trial Type	EFFICACY	CDISC CT
DIAA-2025-001	TE	OBJPRIM	Trial Primary Objective	Assess 7-month HbA1c reduction compared with control	
DIAA-2025-001	TE	SPONSOR	Clinical Study Sponsor	TEST_INST	
DIAA-2025-001	TE	REGID	Registry Identifier	TEST001	
DIAA-2025-001	TE	OUTMSPRI	Primary Outcome Measure	HbA1c	
DIAA-2025-001	TE	OUTMSSEC	Secondary Outcome Measure	GLUCOSE	
DIAA-2025-001	TE	FCNTRY	Planned Country of Investigational Sites	KOR	ISO 3166-1 Alpha-3
DIAA-2025-001	TE	ADAPT	Adaptive Design	N	CDISC
DIAA-2025-001	TE	DCUTDTC	Data Cutoff Date	2025-07-31	ISO 8601
DIAA-2025-001	TE	DCUTDESC	Data Cutoff Description	PRIMARY ANALYSIS	
DIAA-2025-001	TE	NARMS	Planned Number of Arms	2	
DIAA-2025-001	TE	STYPE	Study Type	INTERVENTION	CDISC CT
DIAA-2025-001	TE	INTTYPE	Intervention Type	DRUG	CDISC CT
DIAA-2025-001	TE	INTTYPE	Intervention Type	PLACEBO	CDISC CT
DIAA-2025-001	TE	SSTDTC	Study Start Date	2024-12-01	ISO 8601
DIAA-2025-001	TE	SENDTC	Study End Date	2025-07-31	ISO 8601

STUDYID	DOMAIN	TSPARMCD	TSPARM	TSVAL	TESCDREF
DIAA-2025-001	TE	ACTSUB	Actual Number of Subjects	100	
DIAA-2025-001	TE	HLTSUBJI	Healthy Subject Indicator	N	CDISC CT